Delaware
|
001-34079
|
11-3516358
|
||
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 | Regulation FD Disclosure. |
Item 9.01 | Financial Statements and Exhibits. |
Exhibit No. | Description |
99.1 | Rexahn Pharmaceuticals, Inc. press release dated September 12, 2016, announcing the initiation of stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients. |
REXAHN PHARMACEUTICALS, INC.
|
|
Date: September 12, 2016
|
/s/ Tae Heum Jeong
|
Tae Heum Jeong
|
|
Senior Vice President of Finance and Chief Financial Officer
|
Exhibit No. | Description |
99.1 | Rexahn Pharmaceuticals, Inc. press release dated September 12, 2016, announcing the initiation of stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients. |